InterMune Stock Doubles As Drug Fights Lung Disease
Biotech InterMune (ITMN) reported Tuesday that its drug Esbriet successfully fought off a deadly lung disease in a clinical trial, sending the stock up more than 130% on the stock market today on hopes that the drug will finally be approved in the U.S. The stock is at a 30-month high, near 33. The double-blind, placebo-controlled trial looked at patients with idiopathic pulmonary fibrosis, a disease in which, for unknown reasons, the lungs